Viewing Study NCT04468061


Ignite Creation Date: 2025-12-24 @ 12:12 PM
Ignite Modification Date: 2025-12-30 @ 7:00 PM
Study NCT ID: NCT04468061
Status: RECRUITING
Last Update Posted: 2025-12-05
First Post: 2020-07-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Sponsor: Dana-Farber Cancer Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module